Share Price movement in Healthcare Company $RGC
The Fed is raising interest rates aggressively in an attempt to tame raging inflation and this has been hurting many stock investors who’s seeing bleeding portfolios on their phone or desktops.
Companies are predicted to slash forecasted earnings in the coming earnings quarter due to the high inflation rates and possible slowdown in earnings.
In an interview with MoneyWise earlier this year, Investor Rick Rule said, “I do not believe that the broad equities market will handle multiple rate hikes.”
Rule doesn’t suggest bailing on stocks completely.
This brings to a healthcare stock which had been recently IPO last year July 22’ which had seen a a good run of 300% capital gains after listing. Shares have taken a heavy hit from short sellers and hedge funds whom had strategically targeting the company stock. However RGC had recovered to the $30s, encouraged by study results for Regencell’s RGC-COV19 Traditional Chinese Medicine (TCM) formula for treating COVID-19 symptoms, frequent shareholder communication, and support for the shares in the market.
The formulae candidates aim to address the fundamental causes of disorders while alleviating symptoms and improving overall health at the same time. Taking a holistic approach, RGC’s TCM uses natural ingredients to treat different elements in the body and every bodily function is taken into consideration when preparing the TCM formulae for patients.
Unlike some early-stage companies, where it can be difficult to parse the many ways in which founders and executives may benefit whether or not the company succeeds, RGC has taken a more transparent approach that is well-aligned with shareholders’ long-term interests.
Some highlights about the company executives and founders, showing long term conviction in the company:
- CEO to draw only $1 annual salary and no bonus until the company reaches a $1 billion market capitalization
- CEO to continue company share buyback to demonstrate commitment to the Company and position against short and distort sellers.
- All directors and employees who were previously granted stock options upon the Company’s IPO have agreed to a further lock-up undertaking for a period of six months after their stock options become vested. As their stock options are set to vest on July 16, 2022, their shares will remain locked up until January 16, 2023.
In the next few months, RGC expects to report data from its second clinical study of its standardized TCM formula for the treatment of ASD and ADHD.
We will then findout if the company has been making positve progress on the company when the report becomes available.
[https://scr.zacks.com/news/news-details/2022/RGC-CEO-Figuratively-Putting-His-Money-Where-His-Mouth-Is/default.aspx](https://scr.zacks.com/news/news-details/2022/RGC-CEO-Figuratively-Putting-His-Money-Where-His-Mouth-Is/default.aspx)
The Fed is raising interest rates aggressively in an attempt to tame raging inflation and this has been hurting many stock investors who’s seeing bleeding portfolios on their phone or desktops.
Companies are predicted to slash forecasted earnings in the coming earnings quarter due to the high inflation rates and possible slowdown in earnings.
In an interview with MoneyWise earlier this year, Investor Rick Rule said, “I do not believe that the broad equities market will handle multiple rate hikes.”
Rule doesn’t suggest bailing on stocks completely.
This brings to a healthcare stock which had been recently IPO last year July 22’ which had seen a a good run of 300% capital gains after listing. Shares have taken a heavy hit from short sellers and hedge funds whom had strategically targeting the company stock. However RGC had recovered to the $30s, encouraged by study results for Regencell’s RGC-COV19 Traditional Chinese Medicine (TCM) formula for treating COVID-19 symptoms, frequent shareholder communication, and support for the shares in the market.
The formulae candidates aim to address the fundamental causes of disorders while alleviating symptoms and improving overall health at the same time. Taking a holistic approach, RGC’s TCM uses natural ingredients to treat different elements in the body and every bodily function is taken into consideration when preparing the TCM formulae for patients.
Unlike some early-stage companies, where it can be difficult to parse the many ways in which founders and executives may benefit whether or not the company succeeds, RGC has taken a more transparent approach that is well-aligned with shareholders’ long-term interests.
Some highlights about the company executives and founders, showing long term conviction in the company:
- CEO to draw only $1 annual salary and no bonus until the company reaches a $1 billion market capitalization
- CEO to continue company share buyback to demonstrate commitment to the Company and position against short and distort sellers.
- All directors and employees who were previously granted stock options upon the Company’s IPO have agreed to a further lock-up undertaking for a period of six months after their stock options become vested. As their stock options are set to vest on July 16, 2022, their shares will remain locked up until January 16, 2023.
In the next few months, RGC expects to report data from its second clinical study of its standardized TCM formula for the treatment of ASD and ADHD.
We will then findout if the company has been making positve progress on the company when the report becomes available.
[https://scr.zacks.com/news/news-details/2022/RGC-CEO-Figuratively-Putting-His-Money-Where-His-Mouth-Is/default.aspx](https://scr.zacks.com/news/news-details/2022/RGC-CEO-Figuratively-Putting-His-Money-Where-His-Mouth-Is/default.aspx)
